Initial awakening after an antagonist is not necessarily the final recovery state.
In the randomized day-surgery comparison, remimazolam with flumazenil permitted rapid emergence, but re-sedation was reported in 10.8% and somnolence in 60% of that group. Recovery-unit stay was longer than with propofol. Day-one overall recovery proportions differed numerically without a statistically clear primary comparison.
Patients over sixty-five were excluded. Drug concentrations at antagonist administration were not measured, and the study cannot identify an optimal reversal schedule from these observations alone. Somnolence, re-sedation and a questionnaire-based recovery outcome also represent distinct endpoints.
Record the entire post-reversal observation period. A single responsive examination immediately after flumazenil does not establish sustained alertness. The findings are particularly relevant when evaluating a later change in responsiveness, but individual attribution still requires the dosing timeline, other depressants, respiratory observations and alternative causes.
Source: PMC11129756, supplied full-text paper. Findings are paraphrased; forensic implications are an interpretation.
Related: Etomidate–Midazolam Versus Propofol–Ketamine in Patients With Reduced Ejection Fraction.